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Abstract: Rapid in situ determination of surgical resection margins during 
breast  cancer  surgery  would  reduce  patient  time  under  anesthesia.  We 
present preliminary data supporting the use of a fluorescent glucose analog 
(2-NBDG) as an optical contrast agent to differentiate freshly excised breast 
tissue containing cancerous cells from normal breast tissue. Multi-spectral 
images of 14 breast cancer specimens acquired before and after incubation 
with  2-NBDG  demonstrated  increased  fluorescent  signal  in  all  of  the 
malignant tissue due to increased 2-NBDG consumption. We demonstrate 
that  2-NBDG  has  potential  as  an  optical  contrast  agent  to  differentiate 
cancerous from non-cancerous tissue. 
© 2011 Optical Society of America 
OCIS Codes: (170.1610) Clinical applications; (170.3880) Medical and biological imaging. 
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1. Introduction 
Local recurrence of breast cancer after breast conservation therapy (BCT) can be influenced 
by a variety of risk factors such as age, tumor size, lymph node status, and tumor margins 
[1,2]. Positive margin status, in which malignant cells are present at the resection edge, is 
determinative in prognosis and adjuvant therapy planning. Positive margins often result in a 
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treatments.  In  many  tertiary  care  centers,  appropriate  facilities  and  staff  exist  to  allow 
assessment of margin status intraoperatively. Surgeons in these centers have the opportunity 
to remove more tissue during the same procedure to achieve negative margins if the initial 
resection  margin  is  positive.  However,  many  hospitals  and  smaller  surgery  suites  in  the 
general community do not have pathology support services to allow for intraoperative margin 
assessment, and thus the margin status is not known until several days after the surgery [3]. If 
positive  margins  are  revealed,  patients  face  the  additional  risks  and  costs  of  a  second 
procedure, anxiety, and reduced probability of optimal cosmesis. Therefore, new methods to 
expedite intraoperative assessment of surgical margins are essential. 
Positron Emission Tomography (PET) is currently being used in clinics to stage breast 
cancer  and  monitor  response  to  therapy  [4–6].  It  utilizes  a  positron  emitter  analogue  of 
glucose, 2-(fluorine-18)-(fluoro-2-deoxyglucose) (
18FDG) to monitor in vivo glucose uptake. 
PET leverages the higher metabolic state, higher expression of glucose transporters (GLUTs), 
and lower expression of glucose-6-phosphatase of malignant cells to image the high level of 
18FDG uptake in cancerous cells, distinguishing them from non-cancerous cells [7–12]. 2-[N-
(7-nitrobenz-2-oxa-1,  3-diazol-4-yl)amino]-2-deoxy-d-glucose  (2-NBDG)  is  a  fluorescent 
glucose analogue that undergoes a similar pathway of uptake and metabolism to 
18FDG and 
accumulates preferentially in malignant cells [13,14]. In preclinical imaging studies, 2-NBDG 
accumulation was shown to be higher in cancerous cells than in normal cells [14,15]. Nitin et 
al. have demonstrated the use of 2-NBDG to enhance fluorescent molecular imaging of oral 
neoplasia [15]. 
In  this  study,  we  performed  important  proof  of  principle  study  that  demonstrates  that 
topical application of 2-NBDG can be used as an optical contrast agent to help differentiate 
cancerous tissue using a wide-field imaging system. We imaged fresh human breast tissue 
acquired from surgical specimens and stained them with 2-NBDG. We established that the 2-
NBDG signal in tissue can  be determined using a  wide-field camera and filters to create 
multispectral  images  of  tissue  that  can  then  be  analyzed  both  qualitatively  and  semi-
quantitatively by using the area under the curve metric of the spectral profile of the tissues. 
Our analysis demonstrated  that 2-NBDG preferentially  enhanced the  fluorescent signal of 
malignant  tissue.  Future  steps  will  be  to  develop  a  simpler  and  more  portable  wide-field 
optical system that uses 2-NBDG and can be used to assist in the detection of cancerous tissue 
at the resection site. 
2. Materials and methods 
2.1 2-NBDG characteristics 
2-NBDG was acquired from Invitrogen in powdered form and was resuspended in 1X DPBS 
(Gibco) to a final concentration of 194 μM. The pH of the solution was 7.4. Aliquots of the 
fluorophore were kept frozen at 20°C in black centrifuge tubes until needed. Before receipt 
of the tissue, the aliquots were thawed in a 37°C water bath and kept at that temperature until 
being added to the specimens. 
To evaluate variability in the imaging system in between testing days, 1 ml of 194 μM 2-
NBDG was pipetted into a quartz cuvette and placed in the same position in the imaging 
system and imaged under the same conditions for four consecutive days. The spectra of each 
day was acquired and compared to determine the system’s stability between testing days. 
2.2 Ex vivo tissue acquisition 
Freshly  excised  human  breast  tissue  samples  were  acquired  from  14  patients  undergoing 
surgical resection of suspected breast cancer at The University of Texas MD Anderson Cancer 
Center  with  the  approval  of  the  institutional  review  boards  at  Rice  University  and  MD 
Anderson.  All  patients  gave  written  informed  consent  to  participate.  Each  specimen  was 
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the  specimen.  The  specimen  was  then  breadloafed  in  2-5  mm  increments  and  visually 
inspected and palpated to determine the area of residual tumor. Leftover specimen that was 
not necessary for diagnosis by the surgical pathologist was used for the imaging process. A 
separate  specimen  of  normal  tissue  away  from  the  gross  tumor  was  also  acquired  as  an 
internal control for each patient. For one patient (#2), a single specimen was obtained with 
gross palpable tumor at one end and normal appearing tissue at the other end. Typically, the 
tissues were processed for imaging within 60 minutes of resection. 
2.3 Ex vivo tissue sampling 
Upon receipt of the tissue, autofluorescent images of both normal and malignant tissue were 
acquired using a Maestro wide-field multispectral fluorescent camera (CRi, Woburn, MA). 
The imaging system has a spatial resolution of 25 μm/pixel and the field of view for each 
image acquired was 4.9 X 3.7 cm. The tissue samples were excited with filtered light (445-
490 nm) and the emitted light was filtered (515 nm LP) before entering the camera. The 
exposure time for the camera was 18.56 ms. A multispectral image cube comprised of the 
different images at different wavelengths (520-720 nm, every 10 nm) was created using these 
settings. This process created a prestain image that would be used for comparison after the 
tissue had been stained with 2-NBDG. 
After the prestain image cube was created, both normal and malignant tissue specimens 
were incubated topically with 2-NBDG at 37°C for 20 minutes in the dark. The remaining 2-
NBDG was aspirated and the tissue samples were rinsed twice in cold PBS on ice in the dark 
for 10 minutes. The samples were placed under the wide-field camera in approximately the 
same positions as the prestain images. The tissues were subsequently imaged under the same 
conditions described above, and a poststain multispectral cube was created. 
After  imaging,  the  tissue  samples  were  fixed  in  formalin  for  24  hr,  placed  into  70% 
ethanol, and sent to the research pathology core laboratory at MD Anderson for hematoxylin-
and-eosin (H&E) staining. Both the control and sample tissue slides were then reviewed by a 
breast pathologist (L.M.), who provided a histological diagnosis of the tissue. Pictures of the 
slides were taken at a 40X magnification using an Olympus DP70 camera (Center Valley, 
PA). 
2.4 Fluorescence spectrum acquisition and quantitative analysis 
For semi-quantitative analysis of the images, a region of interest (ROI) was custom-fit along 
the edges of the tissues on the before and after-staining images. The fluorescence spectrum 
from 520 to 720 nm of this ROI was plotted based on the fluorescent signal calculated at 
every 10 nm. The intensity for each wavelength was the average intensity for each pixel in the 
ROI. This allowed the creation of two sets of data for each of the tissues that could be used to 
compare the effect of adding 2-NBDG to both of the tissues. Tissue samples from one patient 
(#10) had only a data set for the post stain image due to a machine malfunction that was not 
detected  until  after  the  tissue  had  been  stained;  however,  samples  from  this  patient  were 
included  because  poststain  comparisons  between  the  cancerous  and  noncancerous  tissues 
could be made. 
Analyses of each tissue spectrum revealed a slight peak in the 560-600 nm range for the 
prestain images and a larger, more prominent peak in the same range for the poststain images. 
To quantify the 2-NBDG signal from each tissue and compare the different samples, an area 
under the peak of each curve (AUC) was calculated by multiplying the height (fluorescent 
signal) of each curve at 580 nm by the width of the peak (40 nm). The area under the prestain 
curves was subtracted from that of the poststain curves to normalize the autofluorescence 
(NAUC). The average NAUC of the cancerous and normal tissue was calculated, as well, the 
mean of all samples was calculated. This mean was then drawn as a horizontal threshold line 
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NAUCs was determined using a two-tailed Student’s t-test. 
The signal differences between the pre and poststain images at each wavelength from 520 
to 720 nm were also calculated for each set of cancerous and normal tissues for the patients. 
For example, the differences at 580 nm for the cancerous tissue from each patient (excluding 
patient #10) were placed into one group and the differences at 580 nm for the normal control 
tissues were also placed into a group. The two groups were then compared by using a two-
tailed student’s t-test; this was done for each wavelength from 520 to 720 nm. 
3. Results 
3.1 Ex vivo tissue characteristics of freshly excised human breast tissue specimens 
The pathologic diagnosis of each tissue sample was confirmed by a breast pathologist in a 
blinded fashion (Table 1). There were five tissues that contained invasive ductal carcinoma 
(IDC), one that contained invasive mammary carcinoma (IMC), three that contained invasive 
lobular carcinoma (ILC), three that contained ductal carcinoma in situ (DCIS), and two that 
contained no cancer cells. Of the two specimens that did not contain cancer cells, one was 
obtained (patient #13) from the periphery of resected breast tissue that did contain metaplastic 
carcinoma with both spindle cell and IDC components. The other tissue sample was from a 
patient  (#14)  who  had  received  neoadjuvant  chemotherapy  and  achieved  a  complete 
pathologic response. In that specimen, there was evidence of tissue repair and fibrosis. 
Table 1. Patient and Sample Characteristics 
Patient/Sample Number  Diagnosis  Nuclear Grade 
1  Ductal Carcinoma in Situ  3 
2  Ductal Carcinoma in Situ  3 
3  Ductal Carcinoma in Situ  3 
4  Invasive Ductal Carcinoma  2 
5  Invasive Ductal Carcinoma  2 
6  Invasive Ductal Carcinoma  2 
7  Invasive Ductal Carcinoma  2 
8  Invasive Ductal Carcinoma  2 
9  Invasive Lobular Carcinoma  3 
10  Invasive Lobular Carcinoma  3 
11  Invasive Lobular Carcinoma  3 
12  Invasive Mucinous Carcinoma  1 
13  No Cancer Cells  N/A 
14  No Cancer Cells  N/A 
3.2 Multispectral image cubes of tissue before and after 2-NBDG incubation 
Figure  1  represents  the  images  acquired  of  both  the  malignant  (IDC)  and  normal  non-
cancerous  tissue  before  and  after  incubation  with  2-NBDG.  These  two  images  are 
representative  of  the  images  analyzed  from  the  malignant  and  normal  tissues.  The  tumor 
specimen clearly showed brighter fluorescent signal after incubation with 2-NBDG (Fig. 1(b), 
T) as compared to its prestained image (Fig. 1(a), T) and the poststain image of the normal 
tissue (Fig. 1(b), N). Each tissue specimen had similarly low-levels of autofluorescence (Fig. 
1(a)).  The  non-neoplastic  tissue  was  mildly  brighter  after  2-NBDG  incubation,  which 
probably reflects the basal level of glucose uptake in normal tissue. Figure 1(c) illustrates a 
representative  H&E  stained  tissue  slice  from  the  tumor  specimen  imaged  in  Fig.  1(b).  It 
confirmed the presence of carcinoma in the tissue with high fluorescent signal. 
Figure 1(d) illustrates the post stain image of a single specimen in which it was unknown 
whether there was presence of malignant tissue. This fluorescent image was used to slice the 
tissue into two different specimens, one that was believed to be cancerous and one that was 
non-cancerous. The presence of DCIS in the left-side aspect and normal tissue in the right-
side aspect of the specimen was confirmed histologically. 
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The fluorescence spectra of the tissues imaged in Fig. 1(a) and 1(b) was calculated and is 
presented in Fig. 2. The spectra are representative of the spectra seen with the other tissues. 
The fluorescent signal of the malignant tissue after 2-NBDG staining was on average 13.1 ± 
1.0 (average ± standard error of the mean) times greater at each wavelength than the signal 
calculated from the prestain image. Conversely, the fluorescence of normal breast tissue was 
only an average of 1.7 ± 0.1 times greater after addition of 2-NBDG. Hence, the fluorescence 
increase after 2-NBDG staining of the malignant tissue was much higher than that of the 
normal,  non-cancerous  control  tissue,  indicating  that  there  was  increased  2-NBDG 
consumption in the malignant tissue relative to the normal tissue. 
Additionally, spectral analysis of the two different slices from Fig. 1(d) showed that the 
intensity at each wavelength was 2.0 ± 0.1 (data not shown) times greater in the malignant 
tissue than the normal tissue for each spectral measurement. This demonstrates that there was 
clear demarcation of an area of high fluorescence corresponding to DCIS and an adjacent low 
level of fluorescence corresponding to normal tissue. 
 
Fig. 1. Wide-field multispectral images of invasive ductal carcinoma (T) and normal breast 
tissue (N) from patient #6. (a) Tissues before being stained with 2-NBDG; (b) tissues after 2-
NBDG staining. Tissues were excited with 445-490 nm light and images were collected after 
having passed through a 515 nm LP filter. (c) Tissue slice stained with hematoxylin and eosin 
depicts IDC. (d) One tissue slice with ductal carcinoma in situ (DCIS) and normal tissue. The 
left, brighter side was diagnosed as DCIS, whereas the other half was diagnosed as normal 
tissue. 
One issue we addressed was if the intensity of 2-NBDG varied on a day-to-day basis. Our 
tests  showed  that  the  intensity  variability  at  each  wavelength  was  less  than  3.2%  of  the 
average intensity calculated for each wavelength over the 4-day period; this demonstrated the 
system’s stability and allowed us to perform quantitative analysis of the images. 
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tumor  samples and  normal controls  were averaged separately at each  wavelength and are 
illustrated in Fig. 3. The difference in the intensity of fluorescence of the tumor samples was 
significantly higher than that of the normal controls at each wavelength from 520 to 720 nm 
(P<0.0001). At 580 nm (the center of the fluorescence spectrum peak ranging from 560 to 600 
nm), the average intensity difference from the malignant tissues (1,878.2 ± 169.7) was 2.7 
times higher than that from the normal non-cancerous tissue (704.9 ± 108.2). 
To quantitatively distinguish the fluorescence of malignant tissue from that of normal, 
non-cancerous  tissue,  the  NAUC  values  for  the  560-600  nm  range  of  the  spectra  were 
calculated for each sample (Fig. 4). The mean NAUC for the tumor samples (81,670 ± 7,142) 
was significantly higher than that for the control (31,170 ± 5,411, P<0.00001). The difference 
between malignant and non-cancerous tissue for some samples (#1, #5, and #10) exceeded a 
factor of 2; however, other tissues (#3, #6, #7, and #8) had less than a 2-fold difference 
between the tissues. The small differences did not seem to be limited to a particular type of 
breast cancer, as IDC had both some of the largest differences and some of the  smallest 
differences. These differences can probably be attributed to each specific tissue and the part of 
the normal breast tissue that was provided by the pathologist. 
Using the average NAUC (56,420) as a discrimination line, the NAUC values for nine of 
the malignant samples were above the line while the NAUC values for three were below. 
However,  the  NAUC  value  of  all  but  one  of  the  normal  control  samples  was  below  the 
threshold. 
 
Fig. 2. Emission spectra of multispectral cubes represented in Fig. 1. Regions of interest were 
hand-drawn on each tissue; fluorescent signals every 10 nm from 520 to 660 nm are shown. 
4. Discussion 
The presence of positive surgical margins is associated with a higher risk of local disease 
relapse [3,16–18]. Typically, it is recommended that patients with positive margins on final 
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[19–21],  both  of  which  carry  additional  risks  for  the  patients.  Therefore,  intraoperative 
evaluation of the surgical resection margins is an important component of the patient care. A 
rapid method of intraoperative margin evaluation could reduce second surgeries for breast 
cancer patients in the general community. 
The study reported here represents an initial step towards the development of an optical 
imaging strategy that would aid both pathologists and surgeons in expediting the process of 
margin  assessment  during  surgery.  Our  study  demonstrates  that  2-NBDG  signal  in  tissue 
specimens  can  be  analyzed  both  qualitatively  and  semi-quantitatively  and  that  wide-field 
fluorescence imaging has the ability to discern malignant from normal tissue. 
 
Fig. 3. Average signal difference between the poststain and prestain images calculated at each 
wavelength. A t-test comparison between the groups at each wavelength revealed that all of the 
groups were statistically different (P<0.0001). Error bars represent standard error of the mean. 
Our strategy is based on the same principles that make PET scans so effective in the 
detection of breast cancer cells in patients. Similar to 
18FDG used in PET scan, 2-NBDG is a 
glucose analogue that is transported into cells via the GLUT1 and GLUT2 transporters [13]. It 
undergoes the same metabolic processes as 
18FDG [14]. Since cancer cells express higher 
levels of GLUTs and lower levels of glucuose-6-phosphatase that metabolizes the glucose 
than normal cells [8–12], both 
18FDG and 2-NBDG accumulate in the cancer cells [22]. This 
process allows PET imaging and fluorescent imaging of the cancer cells using nuclear 
18FDG 
and fluorescent 2-NBDG contrast agents. 
Nitin et al. demonstrated that following topical placement of 2-NBDG, the fluorophore 
entered  the  cancerous  cells  in  both  tissue  phantoms  and  excised  oral  neoplasia  [15];  this 
demonstrated the ability of 2-NBDG to differentiate cancerous cells because of their high 
metabolic activity not because the different extracellular structures found in cancerous tissue 
allow for better 2-NBDG diffusion. As well O’Neil et al. demonstrated that 2-NBDG does 
enter breast cancer cells and at a much higher rate than for non-cancerous cells [14]. 
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excised breast tissue that contained cancer cells from the normal surrounding tissue using our 
ex  vivo  imaging  system.  The  single  specimen  with  DCIS  and  normal  tissue  in  Fig.  1(d) 
demonstrates  how  readily  the  area  of  tissue  with  cancer  cells  can  be  imaged  by  the 
fluorescence from 2-NBDG uptake compared to the adjacent normal tissue and displays the 
potential  of  imaging  tissue  at  the  margin.  By  quantifying  the  fluorescence  signal  through 
spectrum AUC, we were able to set a threshold level that identified 9 out of 12 tissues that 
contained  cancerous  cells.  Hence,  this  strategy  may  be  developed  in  the  future  into  an 
automated  staining  and  quantification  system  to  expedite  the  intraoperative  assessment  of 
excised specimen of tumor margins. With further studies, this strategy could even potentially 
be implemented to assess cancer cells at the surgical margin in vivo. 
Clinical studies had found ILC was associated with lower standard uptake values (SUV) 
[23] and a higher false-negative rate than IDC in PET imaging [8,24–27]. However, our study 
suggests  that  the ILC cells do accumulate  glucose preferentially over  normal surrounding 
tissue. We found all three cancerous tissues that contained ILC showed high fluorescence 
intensity after metabolizing 2-NBDG (Fig. 4). In fact, one had the largest NAUC. Most likely, 
the diffuse growth pattern of ILC does not concentrate the FDG signal high enough beyond 
the resolution limit of the PET imager to generate a high SUV. However, due to the small 
number of samples that contained ILC, this result should be interpreted with caution. 
 
Fig. 4. Areas under each curve for the range of 560-600 nm. Each point on the graph represents 
the difference in AUC between the prestain and poststain images of the tissues from each 
patient.  Dots  represent  the  differences  for  tissues  considered  to  be  cancerous  at  time  of 
collection. The black line represents the average NAUC of the two groups. 
Similar to PET imaging, high basal metabolic state of the patient is likely to influence 
fluorescent glucose imaging of breast cancer. This most likely contributed to the high level of 
fluorescence in the normal breast tissue from patient #13 (Fig. 4). It was the only normal 
control tissue with NAUC above the threshold level. Likewise, the tumor sample obtained 
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specimen. Therefore, similar to the steps implemented prior to the FDG-PET imaging in the 
clinics, the patients’ metabolic state and glucose intake may need to be regulated to optimize 
the use of this strategy. 
Further investigation of this strategy is required before it can be used in clinical settings. 
Foremost, this strategy is expected to have a minimal threshold limit of detection, and thus the 
minimum number of cancerous cells that can be detected by using the ex vivo imaging system 
needs to be determined. For this strategy to be clinically useful, it does not necessarily have to 
detect  all  margin  tissue  with  cancer  cells  because  the  tissue  would  ultimately  undergo 
permanent pathology review after the surgery, which would identify all cancer cells close or at 
the surgical  margin. However, detection of cancer cells at the  margin intraoperatively for 
some  patients  would  spare  those  patients  another  surgical  procedure  for  re-excision  or 
adjuvant radiation treatment intensification. 
In addition, the influence of breast cancer sub-types and treatments the patient received on 
the 2-NBDG uptake and imaging needs to be determined and optimized. In our study, patient 
#14 had received neoadjuvant chemotherapy with trastuzumab prior to her surgery. The tumor 
specimen from this patient had high fluorescence intensity but did not contain cancer cells. 
This elevated fluorescence level could be a result of the increase in immune response and 
activated natural killer cells that was reported in patients with breast cancer that overexpresses 
the  human  epidermal  growth  factor  receptor  2  (HER2)  and  were  treated  with 
chemotherapeutic  drugs  [28,29].  This  is  an  example  of  the  many  factors  that  need  to  be 
considered when considering this technology’s clinical use. 
In  conclusion,  this  study  represents  the  initial  step  towards  the  development  of 
fluorescence imaging system that can improve diagnostic imaging in the clinic. Our goal was 
to develop a method that will optically differentiate malignant from non-cancerous tissue. 
Using this ex vivo  wide-field imaging  system,  we  were able to use a  fluorescent glucose 
analogue  and  tunable  light  filters  to  create  multispectral  images  that  were  analyzed  to 
discriminate  the  presence  of  malignancy  in  excised  tissue.  Our  future  work  includes 
optimizing  an  automated  staining  procedure  so  that  this  process  can  be  an  efficient  and 
effective intraoperative tool for surgeons and pathologists. 
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